Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: There is no information on the use of doxorubicin in horses with tumors. Objective: To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses. Animals: Seventeen horses with 34 localized or multicentric advanced tumors. Methods: Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated. Results: Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed. Conclusion and Clinical Relevance: The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.

Original languageEnglish (US)
Pages (from-to)1209-1217
Number of pages9
JournalJournal of Veterinary Internal Medicine
Volume27
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Equidae
doxorubicin
Doxorubicin
Horses
drug therapy
Drug Therapy
neoplasms
dosage
Hypersensitivity
Maximum Tolerated Dose
Neoplasms
Clinical Protocols
Neutropenia
Appointments and Schedules
horses
hypersensitivity
Histamine Antagonists
neutropenia
Anti-Inflammatory Agents
antihistamines

Keywords

  • Chemotherapy
  • Equine
  • Oncology
  • Oncology treatment

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{7bcbe717eb914273a4e7a923eb84bc84,
title = "Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae",
abstract = "Background: There is no information on the use of doxorubicin in horses with tumors. Objective: To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses. Animals: Seventeen horses with 34 localized or multicentric advanced tumors. Methods: Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated. Results: Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed. Conclusion and Clinical Relevance: The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.",
keywords = "Chemotherapy, Equine, Oncology, Oncology treatment",
author = "Theon, {Alain P} and Nicola Pusterla and Magdesian, {K G} and Wilson, {William D}",
year = "2013",
month = "9",
doi = "10.1111/jvim.12145",
language = "English (US)",
volume = "27",
pages = "1209--1217",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Phase I dose escalation of doxorubicin chemotherapy in tumor-bearing equidae

AU - Theon, Alain P

AU - Pusterla, Nicola

AU - Magdesian, K G

AU - Wilson, William D

PY - 2013/9

Y1 - 2013/9

N2 - Background: There is no information on the use of doxorubicin in horses with tumors. Objective: To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses. Animals: Seventeen horses with 34 localized or multicentric advanced tumors. Methods: Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated. Results: Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed. Conclusion and Clinical Relevance: The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.

AB - Background: There is no information on the use of doxorubicin in horses with tumors. Objective: To determine dose-limiting toxicosis (DLT) and maximum tolerated dose (MTD) of doxorubicin in tumor-bearing horses. Animals: Seventeen horses with 34 localized or multicentric advanced tumors. Methods: Two-stage dose-ranging design involving intrapatient and interpatient dose escalation. Treatment protocol included 6 treatment cycles given at 3-week intervals with dosages ranging from 40 to 85 mg/m2. Clinical signs, hematologic, and nonhematologic changes were evaluated. Results: Total doses ranged from 1,127 to 2,900 mg in 12 horses that completed the assigned treatment protocols. The MTD was 75 mg/m2. Hypersensitivity reactions and neutropenia were dose limiting. Hypersensitivity was dose-dependent but schedule invariant. Neutropenia was dose- and cycle-dependent but dose-escalation schedule invariant. Cardiotoxicity was not observed. Conclusion and Clinical Relevance: The recommended dosage of doxorubicin to treat horses is 70 mg/m2 given at 3-week intervals as single agent. Adjunctive treatment with antihistamines and nonsteroidal anti-inflammatory drugs is recommended to control hypersensitivity.

KW - Chemotherapy

KW - Equine

KW - Oncology

KW - Oncology treatment

UR - http://www.scopus.com/inward/record.url?scp=84884207402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884207402&partnerID=8YFLogxK

U2 - 10.1111/jvim.12145

DO - 10.1111/jvim.12145

M3 - Article

C2 - 23889748

AN - SCOPUS:84884207402

VL - 27

SP - 1209

EP - 1217

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -